Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06805942 · ClinicalTrials.gov registry record · NA
Embolization for the Treatment of Heel Pain Secondary to Plantar Fasciitis
A NA study of Plantar Fasciitis of Both Feet, sponsored by IR Centers.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06805942: Recruiting NA study of Plantar Fasciitis of Both Feet, sponsored by IR Centers.
NCT06805942 is a NA study of Plantar Fasciitis of Both Feet that is actively recruiting participants, run by IR Centers. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06805942, a NA study of Plantar Fasciitis of Both Feet, is actively recruiting participants, sponsored by IR Centers.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the feasibility and safety of using Lipiodol (ethiodized oil) as an investigational embolic agent for treating pain caused by plantar fasciitis. Participants will undergo a minimally invasive procedure called plantar fascia embolization (PFE) to reduce inflammation and pain in the affected area. The study aims to assess changes in pain levels, foot function, and any potential side effects over a six-month follow-up period.
Primary Outcome
Change in pain level as measured by the Visual Analog Scale (VAS), with scores ranging from 0 (no pain) to 10 (worst pain imaginable).
Conditions Studied
Interventions
- DEVICE Lipiodol (ethiodized oil) injection
Study Locations (1)
Virginia
- IR Centers - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-02-15 |
| Est. Completion | 2025-09-30 |
| Phase | NA |
What NCT06805942 shows while recruiting
NCT06805942 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Plantar Fasciitis of Both Feet appearing as the primary indexed condition, and to 1 intervention - of which Lipiodol (ethiodized oil) injection is the first listed.
NCT06805942 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06805942 about?
NCT06805942 is a clinical study titled "Embolization for the Treatment of Heel Pain Secondary to Plantar Fasciitis". This study evaluates the feasibility and safety of using Lipiodol (ethiodized oil) as an investigational embolic agent for treating pain caused by plantar fasciitis. Participants will undergo a minimally invasive procedure called plantar fascia embolization (PFE) to reduce inflammation and pain in t...
What is the current status of trial NCT06805942?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-02-15. Estimated completion is 2025-09-30.
What conditions does trial NCT06805942 study?
This clinical trial studies the following conditions: Plantar Fasciitis of Both Feet.
What interventions are being tested in trial NCT06805942?
The interventions under investigation include: Lipiodol (ethiodized oil) injection (DEVICE).
Who is sponsoring clinical trial NCT06805942?
This trial is sponsored by IR Centers, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06805942 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plantar Fasciitis of Both Feet
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06805942's enrollment target sits among peer trials
10 1928th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI